Multibiotic agents and methods of using the same

A technology of biological agents and vitamins, applied in anti-inflammatory agents, drug combinations, pharmaceutical formulations, etc., can solve the problem of underutilization of small molecules

Inactive Publication Date: 2020-03-06
FLAGSHIP PIONEERING INNOVATIONS V INC
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While therapeutics utilizing the mammalian microbiota have so far focused primarily on probiotics (e.g., live microorganisms) as active agents, small molecules that exploit bidirectional communication remain largely underutilized

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multibiotic agents and methods of using the same
  • Multibiotic agents and methods of using the same
  • Multibiotic agents and methods of using the same

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0388]Preparation of ester-containing multibiological agent

[0389] Ester-containing multibiotics can be prepared using commercially available starting materials, known intermediates, or by using synthetic methods known in the art (e.g., Wuts, P., Greene's Protective Groups in Organic Synthesis [Green's Protective Groups in Organic Synthesis]. ], 5th ed., method described in Wiley [Wiley Press] (2014).

[0390] The following exemplified schemes illustrate methods for preparing the multi-biological agent esters of the present invention. These methods are not limited to the production of the compounds shown, but can also be used to prepare various molecules such as the esters described herein. The compounds of the present invention can also be synthesized by methods not explicitly described in the schemes but within the skill of the art. Compounds can be prepared using readily available materials or known intermediates.

[0391] In the following schemes, Ar is optionally sub...

example 1

[0613] Example 1: [4-[(1E,6E)-7-[4-[2-(1H-indol-3-yl)acetyl]oxy-3-methoxy-phenyl]-3,5 -Dioxo-1,6-dienyl]-2-methoxy-phenyl]2-(1H-indol-3-yl)acetate

[0614] p-curcumin (3g, 8.14mmol, 1 equivalent), 2-(1H-indol-3-yl) acetic acid (7.13g, 40.72mmol, 5 equivalents), EDCI (7.49g, 39.09mmol, 4.8 equivalents) and 4 - A mixture of dimethylaminopyridine (4.78 g, 39.09 mmol, 4.8 equiv) in THF (100 mL) was degassed and washed with N 2 Purge 3 times, and then place the mixture under N 2 Stir at 15 °C for 3 h under atmosphere. The reaction mixture was mixed with brine (100 mL) and extracted with EtOAc (100 mL 3). The organic layer was washed with anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The residue was purified by column (petroleum ether:ethyl acetate=10:1 to 3:1), and concentrated to get crude product. The crude product was further purified by recrystallization from EtOAc (20 mL) to give pure product. (638mg, 935mmol, yield 11%, purity 96.39%) LC / MS: (M+H + ):683....

example 2

[0616] Example 2: 5-Amino-2-butyryloxy-benzoic acid

[0617] step 1:

[0618] at 15°C, N 2 To a mixture of 5-amino-2-hydroxy-benzoic acid (3 g, 19.59 mmol, 1 equiv) in methanol (50 mL) was added Boc in one portion under 2 O (4.28 g, 19.59 mmol, 4.50 mL, 1 equiv). The mixture was stirred at 15 °C for 5 h. The residue was poured into water (100 mL). The aqueous phase was extracted with EtOAc (100 mL), and the organic phase was washed with anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The residue was used in the next step without further purification. 5-(tert-butoxycarbonylamino)-2-hydroxy-benzoic acid (4 g, crude) was obtained as crude product.

[0619] Step 2:

[0620] Add 5-(tert-butoxycarbonylamino)-2-hydroxy-benzoic acid (4 g, 15.79 mmol, 1 equiv) and triethylamine (119.87 mg, 1.18 mmol, 164.88 μL, 1 equiv) at 0 °C in To a solution in THF (30 mL) was added butyryl chloride (126.22 mg, 1.18 mmol, 123.74 μL, 1 equiv) dropwise while maintaining the tempera...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers, or carbamate linkers. The moieties can be alcohol cores, amine cores, and / or acyls. Also disclosed are compositions containing multibiotic agents and methods ofusing the multibiotic agents.

Description

technical field [0001] The present invention relates to multibiological agents comprising two or more moieties linked, for example, by a biodegradable bond. The invention also features compositions containing one or more multi-biological agents and methods of using the multi-biological agents. Background technique [0002] The mammalian microbiota can communicate bidirectionally with the mammalian host system. While therapeutic approaches utilizing the mammalian microbiota have so far focused primarily on probiotics (eg, live microorganisms) as active agents, small molecules that exploit bidirectional communication remain largely underutilized. [0003] Small molecule-based approaches that exploit bidirectional communication between mammalian host systems and mammalian microbes are needed for pharmaceutical and nutraceutical applications. Contents of the invention [0004] In summary, the present invention provides compounds, compositions and methods for regulating human...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7034A61P13/12
CPCA61K31/7034A61P13/12A61K31/05A61K31/09A61K31/122A61K31/137A61K31/14A61K31/155A61K31/353A61K31/366A61K31/606A61P43/00C07C403/24A61K47/54A61K47/549A61K2300/00A61K31/196A61K31/375A61K31/203A61K31/12A61K31/397A61K31/7068A61K38/063A61K31/37A61P3/10A61P9/00A61P29/00A61P21/00A61P17/00A61P1/16A23L33/11A61K9/0014A61K9/0029A61K9/0053A61K9/1623A61K31/164A61K31/192A61K31/197A61K31/205A61K31/355A61K31/592A61K31/702A61K31/728A61K38/08A61K45/06
Inventor J.P.小凯西D.贝里A.卡斯特罗S.J.泰勒F.E.马萨里J.普劳富特E.博加特T.F.布里格斯
Owner FLAGSHIP PIONEERING INNOVATIONS V INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products